Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Children’s Cancer Group Trials

[1]  H. Sather,et al.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Gelber,et al.  Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia , 2000, Cancer.

[3]  A. Oakhill,et al.  FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. , 1999, Medical and pediatric oncology.

[4]  J. Kurtzberg,et al.  Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[6]  F Lampert,et al.  Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. , 1998, Blood.

[7]  M. D. Boer,et al.  Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.

[8]  M. Schrappe,et al.  Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials , 1998, Klinische Padiatrie.

[9]  H. Sather,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.

[10]  H. Prentice,et al.  The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties , 1998, Leukemia.

[11]  H. Sather,et al.  Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Periclou,et al.  The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. , 1998, Anticancer research.

[13]  H. Sather,et al.  Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features , 1998, Cancer.

[14]  A. Bleyer,et al.  National cancer clinical trials: children have equal access; adolescents do not. , 1997, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[15]  J. Downing,et al.  12p Abnormalities and the TEL Gene (ETV6) in Childhood Acute Lymphoblastic Leukemia , 1997 .

[16]  S. Richards,et al.  Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X , 1997, British journal of haematology.

[17]  G. Reaman,et al.  Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Schrappe,et al.  Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Maria Grazia Valsecchi,et al.  Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials , 1997 .

[20]  H. Sather,et al.  Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Bertrand,et al.  Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Downing,et al.  TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H P Koeffler,et al.  TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. , 1996, Blood.

[24]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[25]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[26]  G. Reaman,et al.  Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Buckley,et al.  Young adults 16‐21 years of age at diagnosis entered on childrens cancer group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment , 1993, Cancer.

[28]  H. Sather,et al.  Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Behm,et al.  Hyperdiploid (47-50) acute lymphoblastic leukemia in children. , 1992, Blood.

[31]  Denis R. Miller,et al.  Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure , 1991, Cancer.

[32]  C. Bloomfield,et al.  Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. , 1989, Cancer genetics and cytogenetics.

[33]  J. Ritter,et al.  Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .

[34]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Gadner,et al.  Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen* , 1981 .

[36]  V. Avramis,et al.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[37]  C. Fu,et al.  Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. , 2000, Anticancer research.

[38]  G. Reaman,et al.  Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  K. Weinberg,et al.  Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. , 1989, Cancer research.

[40]  H. Sather,et al.  Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.

[41]  C. R. Pinkerton,et al.  Modified Capizzi maintenance regimen in children with relapsed acute lymphoblastic leukaemia. , 1986, Medical and pediatric oncology.

[42]  H. Sather,et al.  Prolonged second remissions in childhood acute lymphocytic leukemia: a report from the Childrens Cancer Study Group. , 1983, Medical and pediatric oncology.